Sweden leads the world in saving extremely preterm babies
[PRESS RELEASE 2019-03-26] The survival rate among extremely preterm babies has greatly improved in Sweden, a country that offers top-class neonatal care, a study led from Karolinska Institutet published in the esteemed journal JAMA reports.
The researchers have analysed survival among Swedish babies born over 3.5 months prematurely in week 22-26 and compared the statistics from 2014-2016 to those from 2004-2007. All Swedish hospitals participated in the study, which included 2,205 women who had had complications during pregnancy leading to extremely preterm births.
Between these two time periods, the stillbirth rate dropped from 30 to 23 per cent, while the survival rate rose from 70 to 77 per cent. Further, the higher survival was not achieved at the cost of more complications during the neonate period; on the contrary, the researchers observed a reduction in the number of brain and lung damage in the babies born between 2014 and 2016, while the number of other problems, such as eye and abdominal complications, remained unchanged.
“Even if there are individual hospitals around the world that have been able to show similar results for selected patients, the survival of an entire population and for a whole country is world class,” says Mikael Norman, professor of paediatrics at the Department of Clinical Science, Intervention and Technology at Karolinska Institutet in Sweden and the researcher responsible for the study.
By way of comparison, the survival rate for babies born in week 22-26 is around 50 per cent in the UK, France and the USA. And in many comparable countries, it is still rare for babies born in week 22-23 to survive.
The Swedish study found the greatest improvement in survival in babies born in week 22 (from week 22+0 days to week 22+6 days) with birth weights of between 290 and 730 grams. Fifty-eight per cent of those from this group who were admitted to neonatal intensive care between the years 2014 and 2016 survived to at least one year-of-age.
The results suggest that central care support initiatives are effective. In recent years, amendments to laws, guidelines and national recommendations have strengthened healthcare provision and the status of extremely preterm babies. Ultimately though, says Professor Norman, the results of the study are testimony to the capabilities of all the midwives, nurses and doctors who provide pregnant women and their babies the best available care 24 hours a day.
“The profession and the authorities are both good at taking on board new knowledge and translating it into practice,” he says. “Even if certain problems related to adverse events and long-term complications amongst extremely preterm babies remain as vital areas for improvement, I really think that that Swedish neonatal care should fill us with a sense of pride and joy.”
Long-standing national collaboration between researchers and clinicians, and the establishment of the national neonatal quality register are other important contributors.
“It has been essential to make available knowledge on how neonatal care has developed in Sweden,” says Professor Norman.
The study was mainly financed by the Childhood Foundation of the Swedish Order of Freemasons in Stockholm. Mikael Norman has received research grants from the Heart and Lung Foundation and the EU through Horizon 2020. He has also received personal fees from Läkartidningen, the Swedish patient insurance, Liber AB, Studentlitteratur AB and AbbVie AB.
Publication: “Association Between Year of Birth and 1-Year Survival Among Extremely Preterm Infants in Sweden During 2004-2007 and 2014-2016”. Mikael Norman, Boubou Hallberg, Thomas Abrahamsson, Lars J. Björklund, Magnus Domellöf, Aijaz Farooqi, Cathrine Foyn Bruun, Christian Gadsbøll, Lena Hellström-Westas, Fredrik Ingemansson, Karin Källén, David Ley, Karel Maršál, Erik Normann, Fredrik Serenius, Olof Stephansson, Lennart Stigson, Petra Um-Bergström, Stellan Håkansson. JAMA, online 26 March 2019, doi: 10.1001/jama.2019.2021.
For more information, please contact:
Mikael Norman, professor
Department of Clinical Science, Intervention and Technology, Karolinska Institutet
Phone: +46 70 002 10 07
Email: mikael.norman@ki.se
Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Tags:
